PhaseBio Pharmaceuticals Inc. Stock News

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor

PhaseBio Pharma (PHAS) said manufacturing of its lead candidate, bentracimab, drug substance and drug product process performance qualification, which required multiple commercial…

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS ) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study. The Company will analyze the … Full story available on Benzinga.com

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on man

Wall Street brokerages forecast that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) will post sales of $4.91 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for PhaseBio Pharmaceuticals earnings. The highest sales estimate is $9.33 million and the lowest is $500,000.00. The firm is scheduled to announce its next earnings results []

In the last trading session, 1.62 million shares of the PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) were traded. Most recently the companys share price was $2.36, and it changed around -$0.18 or -7.09% from the last close, which brings the market valuation of the company to $122.11M. PHAS currently trades at a discount to its 52-week high Lets Talk About How PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) Stock Is Doing. Read More »

PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.

Equities research analysts expect PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) to report sales of $4.91 million for the current quarter, according to Zacks. Two analysts have issued estimates for PhaseBio Pharmaceuticals earnings, with estimates ranging from $500,000.00 to $9.33 million. The company is expected to report its next quarterly earnings report on Monday, March 21st. On average, []

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS ) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding. Bentracimab was shown to reverse the effects of AstraZeneca Plc''s (NASDAQ: AZN ) blood thinner Brilinta (ticagrelor) in an interim Full story available on Benzinga.com

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included pati

10 penny stocks to watch this week. The post 10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentr